美迪西(688202) - 2021 Q3 - 季度财报

Financial Performance - Revenue for Q3 2021 reached ¥301,253,455.71, an increase of 74.61% year-over-year, and total revenue for the year-to-date was ¥786,298,234.85, up 81.62% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2021 was ¥67,850,765.16, representing a 141.67% increase year-over-year, while year-to-date net profit was ¥180,954,043.22, up 142.06% compared to the same period last year[8]. - Basic earnings per share for Q3 2021 was ¥1.09, reflecting a 142.22% increase year-over-year, with diluted earnings per share also at ¥1.09[12]. - Total operating revenue for the first three quarters of 2021 reached ¥786,298,234.85, a significant increase from ¥432,937,345.40 in the same period of 2020, representing an increase of approximately 81.5%[42]. - Net profit for the first three quarters of 2021 was ¥183,378,709.53, compared to ¥77,840,671.33 in 2020, reflecting an increase of approximately 135.4%[49]. - The total comprehensive income for the period attributable to the parent company was CNY 180,954,043.22, compared to CNY 74,756,419.87 in the same period last year, representing an increase of approximately 141.4%[50]. - Basic and diluted earnings per share were both CNY 2.92, up from CNY 1.21 in the previous year, indicating a growth of 141.3%[50]. Research and Development - Research and development expenses totaled ¥21,899,764.33 for Q3 2021, a 99.52% increase year-over-year, and accounted for 7.27% of revenue[12]. - The company continues to enhance its R&D capabilities to strengthen competitive advantages and increase business capacity[20]. - Research and development expenses for the first three quarters were ¥56,019,615.62, compared to ¥30,248,325.68 in 2020, indicating an increase of approximately 85.5%[45]. Assets and Liabilities - Total assets as of the end of Q3 2021 were ¥1,597,558,059.75, a 17.10% increase from the end of the previous year[12]. - The company's total assets increased to ¥1,597,558,059.75 from ¥1,364,323,129.19, marking a growth of about 17.1%[42]. - Non-current liabilities rose to ¥70,704,845.58 from ¥32,528,148.94, showing an increase of approximately 117.8%[42]. - The total liabilities of the company reached ¥386,930,373.15, up from ¥228,669,309.25, which is an increase of about 69.2%[42]. - Total non-current assets amounted to 665,033,566.75, a decrease from 716,835,214.07, reflecting a reduction of 7.1%[58]. - Current liabilities totaled 196,141,160.31, compared to 206,422,694.30, showing a decrease of 4.9%[61]. - Total liabilities were 228,669,309.25, down from 279,163,594.49, representing a reduction of 18.1%[61]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥201,011,355.90, reflecting a 71.42% increase compared to the same period last year[12]. - Cash inflows from operating activities totaled CNY 800,472,828.02, compared to CNY 480,815,789.06 in the same period last year, reflecting an increase of approximately 66.5%[54]. - Net cash flow from operating activities was CNY 201,011,355.90, up from CNY 117,265,411.30, marking a growth of about 71.3%[54]. - The company reported a net increase in cash and cash equivalents of negative CNY 96,371,156.12, compared to negative CNY 230,241,669.22 in the previous year, indicating an improvement in cash flow management[56]. - The company's cash and cash equivalents as of September 30, 2021, were ¥369,577,301.82, down from ¥465,948,457.94 at the end of 2020, representing a decrease of approximately 20.67%[37]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 4,527[23]. - The largest shareholder, Chen Jinzhan, holds 9,722,588 shares, accounting for 15.68% of total shares[23]. - The top ten unrestricted shareholders include major investment funds, with the largest being the China Industrial Bank - Central European Medical Health Mixed Securities Investment Fund, holding 3,034,138 shares, or 4.89%[27]. - The company has not reported any significant changes in shareholder pledges or frozen shares[23]. Corporate Governance and Strategy - The company is focused on enhancing its corporate governance structure and attracting core technical personnel through an incentive plan[33]. - The company maintains a cash flow management strategy to ensure liquidity amid changing market conditions[64]. - Future outlook includes potential market expansion and new product development initiatives[64].